Accelerated Partial Breast Irradiation

Meattini, Icro; Kim, Kyubo; Livi, Lorenzo

doi:10.1097/coc.0000000000000968

Cited by 2 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Survival strongly depends on the tumor stage and subtype at diagnosis (3). Local recurrence occurs in <2-10% of all patients after breast-conserving surgery and radiotherapy, and in 4% of cases after mastectomy within five years (4)(5)(6)(7)(8)(9)(10). Patients who suffer from a loco(regional) recurrence have an increased risk of dying from breast cancer compared to those without recurrence (11,12).…”

Section: Introductionmentioning

confidence: 99%

“…with a total dose of 40 Gy and single doses of 2.67 Gy/5x per week or 27 Gy in five fractions within one week, have also proven to be safe and effective. These alternative regimens offer the advantage of significantly reducing the burden of treatment for the patients due to shorter duration of the therapy (7)(8)(9)(10). Approximately 60% of patients, regardless of tumor stages, receive radiotherapy (3).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

Thomsen,

Sahlmann,

Bronsert

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

IntroductionBreast cancer is globally the leading cancer in women, and despite the high 5-year survival rate the most frequent cause of cancer related deaths. Surgery, systemic therapy and radiotherapy are the three pillars of curative breast cancer treatment. However, locoregional recurrences frequently occur after initial treatment and are often challenging to treat, amongst others due to high doses of previous radiotherapy treatments. Radiotherapy can be combined with local hyperthermia to sensitize tumor cells to radiation and thereby significantly reduce the required radiation dose. Therefore, the combination treatment of mild local hyperthermia, i.e. locally heating of the tissue to 39-43°C, and re-irradiation with a reduced total dose is a relevant treatment option for previously irradiated patients. The mechanisms of this effect in the course of the therapy are to date not well understood and will be investigated in the HISTOTHERM study.Methods and analysesPatients with local or (loco)regional recurrent breast cancer with macroscopic tumors are included in the study. Local tumor control is evaluated clinically and histologically during the course of a combination treatment of 60 minutes mild superficial hyperthermia (39 - 43°C) using water-filtered infrared A (wIRA) irradiation, immediately followed by hypofractionated re-irradiation with a total dose of 20-24 Gy, administered in weekly doses of 4 Gy. Tumor and tumor stroma biopsies as well as blood samples will be collected prior to treatment, during therapy (at a dose of 12 Gy) and in the follow-up to monitor therapy response. The treatment represents the standard operating procedure for hyperthermia plus re-irradiation. Various tissue and blood-based markers are analyzed. We aim at pinpointing key mechanisms and markers for therapy response which may help guiding treatment decisions in future. In addition, quality of life in the course of treatment will be assessed and survival data will be evaluated.RegistrationThe study is registered at the German Clinical Trials Register, Deutsches Register Klinischer Studien (DRKS00029221).

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

Thomsen,

Sahlmann,

Bronsert

et al. 2023

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Meattini et al [ 52 ] proposed a potential personalised RT algorithm for early‐stage, low‐risk breast cancer on the basis of genome data. Currently, international recommendations in favour of PBI over WBI are based on clinicopathological risk factors [ 35 , 53 ].…”

Section: Future Directionsmentioning

confidence: 99%

Accelerated partial breast irradiation: Current evidence and future developments

Song,

Zhang,

Ren

et al. 2024

Cancer Innovation

View full text Add to dashboard Cite

Whole breast irradiation after breast‐conserving surgery for early breast cancer has become one of the standard treatment modes for breast cancer and yields the same effect as radical surgery. Accelerated partial breast irradiation (APBI) as a substitute for whole breast irradiation for patients with early breast cancer is a hot spot in clinical research. APBI is characterised by simple high‐dose local irradiation of the tumour bed in a short time, thus improving convenience for patients and saving costs. The implementation methods of APBI mainly include brachytherapy, external beam radiation therapy, and intraoperative radiotherapy. This review provides an overview of the clinical effects and adverse reactions of the main technologies of APBI and discusses the prospects for the future development of APBI.

show abstract

Accelerated Partial Breast Irradiation

Cited by 2 publications

References 38 publications

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

Protocol of the HISTOTHERM study: assessing the response to hyperthermia and hypofractionated radiotherapy in recurrent breast cancer

Accelerated partial breast irradiation: Current evidence and future developments

Contact Info

Product

Resources

About